Fatal Meningitis in Patient with X-Linked Chronic Granulomatous Disease Caused by Virulent Granulibacter bethesdensis by Rebelo, M et al.
DISPATCHES
976 Emerging Infectious Diseases • www.cdc.gov/eid •  Vol. 25, No. 5, May 2019
Mafalda Rebelo,1 Li Ding,1 Ana Isabel Cordeiro, 
Conceição Neves, Maria João Simões,  
Adrian M. Zelazny, Steven M. Holland,2  
João Farela Neves2
Granulibacter bethesdensis is a pathogen reported to cause 
recurrent lymphadenitis exclusively in persons with chronic 
granulomatous disease. We report a case of fatal meningitis 
caused by a highly virulent G. bethesdensis strain in an ado-
lescent in Europe who had chronic granulomatous disease.
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by a deficient nico-
tinamide adenine dinucleotide phosphate oxidative burst 
that impairs phagocyte superoxide formation and killing 
of certain pathogens. Mutations can occur in any of the 5 
subunits of nicotinamide adenine dinucleotide phosphate 
oxidase. Most cases are inherited as X-linked defects (gp-
91phox), but they also can occur in an autosomal recessive 
manner (1). Increased susceptibility develops to recurrent 
infections of the skin, lymph nodes, lungs, and other organs 
(2), mostly caused by bacteria and fungi, including Staphy-
lococcus aureus, Serratia marcescens, Burkholderia cepa-
cia, Salmonella spp., Nocardia spp., and Aspergillus spp. 
(2). Emerging organisms, such as Granulibacter bethes-
densis and other methylotrophs, occur almost exclusively 
in CGD patients (3,4).
G. bethesdensis was first described in 2006, when it 
was isolated in a CGD patient with lymphadenitis (4). It 
is a gram-negative, aerobic, oxidase-negative, catalase-
positive, nonmotile coccobacillus to rod-shaped bacte-
rium belonging to the Acetobacteraceae family (5,6). 
G. bethesdensis was the first of these Acetobacteraceae 
family bacteria with proven pathogenicity in humans, 
causing invasive disease in CGD patients and mice (4). It 
has been mostly linked to indolent nonfatal lymphadenitis 
and deep neck infections in patients in North America. 
The infection can recur over several years by reactiva-
tion of the same strain or reinfection with different strains 
(3,7–9). The first fatal infection was reported in a 10-year-
old boy from Spain, who died of fulminant sepsis (10). In 
vitro, G. bethesdensis shows extensive resistance to vari-
ous antimicrobial drugs, although its slow growth makes 
susceptibility testing difficult. Ceftriaxone, aminoglyco-
sides, doxycycline, and trimethoprim/sulfamethoxazole 
showed activity in vitro (7).
We report a case of G. bethesdensis meningitis in a pa-
tient with X-linked CGD. We also report animal data com-
paring this G. bethesdensis strain with the strain recovered 
from recurrent lymphadenitis in a US CGD patient.
The Study
The patient was a 16-year-old boy whose X-linked CGD 
(CYBB exon 13 deletion) was diagnosed when he was 2 
years old. His disease had been well-controlled with co-
trimoxazole, itraconazole, and interferon-γ. In September 
2014, he was hospitalized with a deep cervical abscess 
(Figure 1, panel A) and received a 5-week course of in-
travenous ciprofloxacin, doxycycline, and ceftriaxone that 
resulted in complete clinical and radiologic resolution, fol-
lowed by 6 weeks of oral amoxicillin/clavulanic acid, dox-
ycycline, and ciprofloxacin along with his usual prophy-
laxis. No pathogen was identified despite blood cultures, 
bronchoalveolar lavage, and lymph node biopsy cultures 
and broad-range bacterial PCR.
After this regimen was completed, the boy was re-
admitted for 8 weeks with pneumonia with pleural effu-
sion (Figure 1, panel B). Full 16S rRNA gene sequencing 
(≈1,500 bp) identified Cupriavidus spp. in pleural fluid. He 
received meropenem, amikacin, ciprofloxacin, teicoplanin, 
doxycycline, and voriconazole, and his condition im-
proved. However, 2 weeks later, fever returned, along with 
splenomegaly, hemodynamic instability, pancytopenia, 
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hypofibrinogenemia, hyperferritinemia, and elevated solu-
ble CD25. He received intravenous immunoglobulin and 
dexamethasone for this inflammatory condition and fully 
recovered. Neck and lung computed tomography images 
and positron emission tomography performed 1 month later 
showed no signs of active infection.
Nevertheless, a few days later, the patient sought care 
for altered mental status, hallucinations, aggressiveness, and 
respiratory instability requiring admission to the pediatric in-
tensive care unit. He had extensive bilateral pneumonia and 
multiple intraparenchymal brain abscesses (Figure 1, panel 
C). Meropenem, ciprofloxacin, amikacin, doxycycline, 
Figure 1. Most relevant imaging results from a 16-year-old boy with X-linked chronic granulomatous disease who died of meningitis caused by 
a virulent Granulibacter bethesdensis strain. A) Computed tomography image showing deep cervical abscess (arrow), July 2012. B) Radiograph 
showing pneumonia with pleural effusion, October 2012. C) Cranial magnetic resonance image showing multiple intraparenchymal brain 
abscesses (arrows), December 2012. D) The patient died of obstructive hydrocephalus (shown) and multiorgan failure, April 2013.
Figure 2. Granulibacter bethesdensis colonies and pathology results after inoculation on mouse models. A, B) CSF on chocolate agar 
for 4 days showed slowly growing brown-yellow, shiny colonies 2–4 mm in diameter. Full 16S RNA sequencing (≈1,500 bp) led to 
identification of G. bethesdensis (with 99.7% match). C) Survival of gp91/p47 KO mice after inoculation of different G. bethesdensis 
strains. D) Pathology images of gp91 KO mouse lung after CSF strain infection. E) Pathology images of gp91 KO mouse lungs after type 
strain infection. F) Quantification of G. bethesdensis strains in spleens of gp91/p47 KO mice after inoculation. CSF, cerebrospinal fluid; 
type, National Institutes of Health type strain; WT, wild type.
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teicoplanin, and voriconazole were started; results of ce-
rebrospinal fluid (CSF) and lung biopsy samples were 
unremarkable. Teicoplanin was switched to linezolid and 
voriconazole to caspofungin and liposomal amphotericin 
B because of toxicity concerns. Four weeks later, he was 
discharged from the intensive care unit. One month later, 
fever, vomiting, and focal neurologic deficits developed. 
CSF showed pleocytosis and hypoglycorrhachia with el-
evated protein levels. Cerebral imaging confirmed lepto-
meningitis. Isoniazid, clarithromycin, and rifampin were 
added to his treatment regimen, but his neurologic status 
continued to deteriorate. Obstructive hydrocephalus (Fig-
ure 1, panel D) and multiorgan failure developed, and he 
died 3 months later.
CSF cultures yielded yellow-brown, shiny, small 
colonies (2–4 mm) on chocolate agar after 4 days’ incu-
bation. (Figure 2, panels A, B). Full 16S RNA sequenc-
ing (≈1,500 bp) showed 99.7% match to the type strain of 
G. bethesdensis CGDNIH1T (ATCC BAA-1260T, DSM 
17861T) from North America and 100% match to a previ-
ously reported G. bethesdensis strain from Spain. Non-
standardized susceptibility test using Etest, performed in 
Mueller Hinton agar supplemented with 5% sheep blood 
agar with an overnight air incubation at 37°C, showed re-
sistance to doxycycline (MIC 24 mg/L) and ceftriaxone 
(MIC >32 mg/L).
We used mouse models of CGD to determine whether 
differences existed in immune response, pathogenicity, or 
severity of disease between the European (CSF strain) and 
the US (type strain) strains. We intraperitoneally infected 
gp91phox−/− mice with 107 CFU of G. bethesdensis type 
strain and p47phox−/− mice intraperitoneally with 107 CFU 
of CSF strain and monitored moribundity during infection. 
We euthanized gp91phox−/− mice 4 weeks and p47phox−/−mice 
8 weeks after infection and collected brain, spleen, lung, 
lymph nodes, and blood for culture, bacterial enumera-
tion, and histopathologic examination. Plasma cytokines 
were assayed.
Although we observed differences between gp91phox−/− 
and p47pho−/− mice, both CGD mice models showed high 
rates of death when infected with CSF strain. No deaths 
occurred in mice infected with type strain, nor did CSF 
strain cause disease in wild-type mice (Figure 2, panel C). 
CSF strain–infected mice showed more severe pathologic 
organ changes than did type strain–infected mice (Figure 2, 
panels D, E; Appendix Figure 1, https://wwwnc.cdc.gov/
EID/article/25/5/18-1505-App1.pdf). We performed quan-
titative cultures to assess bacterial load in the spleens of 
inoculated mice. CSF strain CFUs were 100–1,000 times 
higher than those of type strain 4 and 8 weeks after in-
fection. (Table; Figure 2, panel F). In addition, infection 
with CSF strain yielded 100–1,000 times higher CFUs in 
spleens of CGD mice than in wild-type mice 4 and 8 weeks 
after infection. (Appendix Figure 2). CSF strain showed 
faster growth on solid and in liquid media and a higher op-
timal growth temperature (37°C) than previously described 
North America lymph node isolates (Appendix Figure 3). 
CGD mice infected with CSF strain showed higher plasma 
interleukin-1β, tumor necrosis factor–α, and interleukin-6 
than those infected with type strain 4 and 8 weeks after 
infection, which correlated with differences in tissue bacte-
rial load. Cytokine levels did not increase in wild-type mice 
infected with CSF strain (Appendix Figure 4).
Conclusions
G. bethesdensis is an emerging pathogen shown to cause 
infection exclusively in CGD patients and has a spectrum 
of disease severity ranging from chronic and recurrent in-
fections to fulminant sepsis, central nervous system infec-
tion, and death (3,7,10). Until recently, all reported North 
America cases were nonfatal chronic infections; 1 case 
from Europe (Spain) was fatal. Recently, Mayer et al. re-
ported an X-linked CGD patient in the United States who 
died of fulminant infection with an organism with 100% 
identity to 500 bp of G. bethesdensis 16S (11). Unfortu-
nately, that G. bethesdensis isolate was not available for 
analysis and comparison with other G. bethesdensis strains. 
The previous strain from Europe was highly resistant to an-
timicrobial agents, including colistin, most β-lactams, and 
quinolones (10).
We found that a CSF G. bethesdensis strain, showing 
an identical 16S sequence to a previously described ful-
minant strain from Europe, was more virulent and lethal 
in a mouse model than the G. bethesdensis US type strain 
and more virulent in gp91phox−/− than in p47 phox−/− mice. 
A fatal case of G. bethesdensis infection in the United 
States suggests that heterogeneity might exist among 
North America G. bethesdensis strains. Bacterial genome 
sequencing may identify discrete virulence factors. G. 
bethesdensis must be included as a cause of fatal dissemi-
nated infection in CGD.
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Table. Bacterial culture from blood and brain samples of gP91 





gp91/, n = 10 Type, USA 0 0 
gp91/, n = 10 CSF, Portugal 5 2 
p47/, n = 5 Type 0 0 
p47/, n = 5 CSF 0 0 
WT, n = 9 CSF, Portugal 0 ND 
*Bold indicates the results of the inoculation of CSF strain in the gp91 KO 
mouse. CSF, cerebrospinal fluid; ND, not done; WT, wild type.  
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